Home Invivo Functional Antibodies Immunology & Inflammation CD markers Anti-mouse/human/rat CD47 (IAP)-InVivo
For research use only. Not for use in humans.

Anti-mouse/human/rat CD47 (IAP)-InVivo

Clone No.：MIAP410

Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells.

Anti-mouse/human/rat CD47 (IAP)-InVivo

Click to purchase the isotype control of Anti-mouse/human/rat CD47 (IAP)-InVivo

Quality Control

Batch: Purity: 99% Protein concentration: 6.07 mg/ml Endotoxin Level: ＜1EU/mg
99

Product Details

Clone MIAP410
Isotype Mouse IgG1, κ
Application Anti-mouse/human/rat CD47 (IAP)-InVivo
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS, pH 7.0 Contains no stabilizers or preservatives
Murine Pathogen Screening Panel all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus.
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082259 ACTIVE_NOT_RECRUITING Drug: ASTX660|Drug: Pembrolizumab Advanced Cancer; Cervical Cancer; Triple Negative Breast Cancer Institute of Cancer Research, United Kingdom 2022-03-02 PHASE1
NCT06224868 UNKNOWN Cholecystitis Baskent University 2024-01-15
NCT03871959 COMPLETED Drug: Pembrolizumab|Drug: DEBIO1143 Adenocarcinoma of the Pancreas; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum Centre Leon Berard 2019-09-15 PHASE1
NCT03547986 UNKNOWN Peripheral Arterial Disease Biotronik AG 2018-11-09
NCT01908413 TERMINATED Drug: CUDC-427 Lymphoma Curis, Inc. 2013-07 PHASE1
NCT01831232 COMPLETED Drug: pravastatin sodium|Drug: idarubicin|Drug: cytarabine Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia Fred Hutchinson Cancer Center 2013-05

(data from https://clinicaltrials.gov, updated on 2026-06-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.